Literature DB >> 23279628

Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia.

Sun K Kim1, Roberto Romero, Zeynep A Savasan, Yi Xu, Zhong Dong, Deug-Chan Lee, Lami Yeo, Sonia S Hassan, Tinnakorn Chaiworapongsa.   

Abstract

OBJECTIVE: Cross-talk between inflammation and angiogenesis pathways has been recently reported. The objectives of this study were to: (i) examine whether amniotic fluid (AF) concentrations of soluble endoglin (sEng), a protein with anti-angiogenic properties, change during pregnancy, parturition, or intra-amniotic infection and/or inflammation (IAI); (ii) determine whether an increase in sEng in the AF of patients with preterm labor (PTL) and preterm prelabor rupture of membranes (PROM) is associated with adverse neonatal outcomes; and (iii) investigate potential sources of sEng in AF. STUDY
DESIGN: A cross-sectional study was conducted to include patients in the following groups: (i) mid-trimester (n = 20); (ii) PTL with term delivery (n = 95); (iii) PTL leading to preterm delivery with (n = 40) and without IAI (n = 46); (iv) preterm PROM with (n = 37) and without IAI (n = 37); (v) term in labor (n = 48) and not in labor (n = 44). AF concentrations of sEng were determined by enzyme-linked immunosorbent assay. Chorioamniotic membranes, umbilical cord blood, and AF macrophages were examined for the expression of endoglin.
RESULTS: (i) Patients with IAI had a higher median AF concentration of sEng than those without IAI (P = 0.02 for PTL and 0.06 for preterm PROM); (ii) AF concentrations of sEng in the 3rd and 4th quartiles were associated with IAI (OR 2.5 and 7.9, respectively); (iii) an AF sEng concentration ≥779.5 pg/mL was associated with bronchopulmonary dysplasia (BPD) (OR 7.9); (iv) endoglin was co-localized with CD14+ macrophages in AF pellets of patients with IAI by immunofluorescence and flow cytometry; and (v) the concentration of sEng in the supernatant was significantly increased after the treatment of macrophages with endotoxin or TNF-α.
CONCLUSIONS: Soluble endoglin participates in the host response against IAI. Activated macrophages may be a source of sEng concentrations in the AF of patients with IAI. An increase of sEng in the AF is associated with BPD and adverse neonatal outcomes. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23279628      PMCID: PMC4151572          DOI: 10.1111/aji.12046

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  173 in total

1.  Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes.

Authors:  Roberto Romero; Digna R Velez Edwards; Juan Pedro Kusanovic; Sonia S Hassan; Shali Mazaki-Tovi; Edi Vaisbuch; Chong Jai Kim; Tinnakorn Chaiworapongsa; Brad D Pearce; Lara A Friel; Jacquelaine Bartlett; Madan Kumar Anant; Benjamin A Salisbury; Gerald F Vovis; Min Seob Lee; Ricardo Gomez; Ernesto Behnke; Enrique Oyarzun; Gerard Tromp; Scott M Williams; Ramkumar Menon
Journal:  Am J Obstet Gynecol       Date:  2010-05       Impact factor: 8.661

2.  Clinical significance of early (< 20 weeks) vs. late (20-24 weeks) detection of sonographic short cervix in asymptomatic women in the mid-trimester.

Authors:  E Vaisbuch; R Romero; O Erez; J P Kusanovic; S Mazaki-Tovi; F Gotsch; V Romero; C Ward; T Chaiworapongsa; P Mittal; Y Sorokin; S S Hassan
Journal:  Ultrasound Obstet Gynecol       Date:  2010-10       Impact factor: 7.299

3.  A role for TLRs in the regulation of immune cell migration by first trimester trophoblast cells.

Authors:  Vikki M Abrahams; Irene Visintin; Paulomi B Aldo; Seth Guller; Roberto Romero; Gil Mor
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

4.  Chronic lung disease after premature birth.

Authors:  Ernest Cutz; David Chiasson
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

5.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

6.  Immunohistochemical distribution of toll-like receptor 4 in preterm human fetal membrane.

Authors:  Seong Jin Choi; Soon-Hee Jung; Minseob Eom; Kyoung Hee Han; In-Bai Chung; Soo-Ki Kim
Journal:  J Obstet Gynaecol Res       Date:  2011-08-10       Impact factor: 1.730

7.  Chorioamnionitis and inflammation of the fetal lung.

Authors:  B Schmidt; L Cao; S Mackensen-Haen; H Kendziorra; K Klingel; C P Speer
Journal:  Am J Obstet Gynecol       Date:  2001-07       Impact factor: 8.661

8.  Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization.

Authors:  Bernard Thébaud; Faruqa Ladha; Evangelos D Michelakis; Monika Sawicka; Gavin Thurston; Farah Eaton; Kyoko Hashimoto; Gwyneth Harry; Alois Haromy; Greg Korbutt; Stephen L Archer
Journal:  Circulation       Date:  2005-10-18       Impact factor: 29.690

9.  The importance of intra-amniotic inflammation in the subsequent development of atypical chronic lung disease.

Authors:  Joonho Lee; Kyung Joon Oh; Hye Jin Yang; Joong Shin Park; Roberto Romero; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2009-10

10.  TLR6 modulates first trimester trophoblast responses to peptidoglycan.

Authors:  Vikki M Abrahams; Paulomi B Aldo; Shaun P Murphy; Irene Visintin; Kaori Koga; Gabriella Wilson; Roberto Romero; Surendra Sharma; Gil Mor
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

View more
  6 in total

1.  [Effect of premature rupture of membranes on maternal infections and outcome of preterm infants].

Authors:  Tian Wu; Jing Shi; Shan Bao; Yi Qu; De-Zhi Mu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-08

2.  Clinical chorioamnionitis at term IV: the maternal plasma cytokine profile.

Authors:  Roberto Romero; Piya Chaemsaithong; Nikolina Docheva; Steven J Korzeniewski; Adi L Tarca; Gaurav Bhatti; Zhonghui Xu; Juan P Kusanovic; Zhong Dong; Noppadol Chaiyasit; Ahmed I Ahmed; Bo Hyun Yoon; Sonia S Hassan; Tinnakorn Chaiworapongsa; Lami Yeo
Journal:  J Perinat Med       Date:  2016-01       Impact factor: 1.901

3.  Clinical chorioamnionitis at term III: how well do clinical criteria perform in the identification of proven intra-amniotic infection?

Authors:  Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Juan P Kusanovic; Nikolina Docheva; Alicia Martinez-Varea; Ahmed I Ahmed; Bo Hyun Yoon; Sonia S Hassan; Tinnakorn Chaiworapongsa; Lami Yeo
Journal:  J Perinat Med       Date:  2016-01       Impact factor: 1.901

4.  Oxidative injury of the pulmonary circulation in the perinatal period: Short- and long-term consequences for the human cardiopulmonary system.

Authors:  Daphne P de Wijs-Meijler; Dirk J Duncker; Dick Tibboel; Ralph T Schermuly; Norbert Weissmann; Daphne Merkus; Irwin K M Reiss
Journal:  Pulm Circ       Date:  2017-01-01       Impact factor: 3.017

5.  Prediction of emergency cerclage outcomes in women with cervical insufficiency: The role of inflammatory, angiogenic, and extracellular matrix-related proteins in amniotic fluid.

Authors:  Kyong-No Lee; Kyo Hoon Park; Yu Mi Kim; Iseop Cho; Tae Eun Kim
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.240

6.  Untargeted Metabolomic Analysis of Amniotic Fluid in the Prediction of Preterm Delivery and Bronchopulmonary Dysplasia.

Authors:  Eugenio Baraldi; Giuseppe Giordano; Matteo Stocchero; Laura Moschino; Patrizia Zaramella; Maria Rosa Tran; Silvia Carraro; Roberto Romero; Maria Teresa Gervasi
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.